Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma

You may be eligible if

• Histologically confirmed malignancy at either original diagnosis or relapse, including the following:
• * Solid tumor, including primary CNS tumors
• * Neurologic deficits in patients with CNS tumors must have been relatively stable for ≥ 1 week
• * Patients with CNS tumors must be on stable or decreasing doses of dexamethasone for the past 7 days
• * Histology requirement waived for intrinsic brain stem tumors
• * Lymphoma
• Measurable or evaluable disease
• No known curative therapy or no therapy proven to prolong survival with an acceptable quality of life exists
• Patients with known bone marrow metastases are eligible for study but are not evaluable for hematologic toxicity
• * Not known to be refractory to red blood cell or platelet transfusions
• Karnofsky performance score (PS) 60-100% (\> 10 years of age) or Lansky PS 60-100% (≤ 10 years of age)
• Absolute neutrophil count ≥ 1,000/mm³
• Platelet count ≥ 100,000/mm³ (transfusion independent, defined as not receiving platelet transfusions within a 7-day period prior to study enrollment)
• Hemoglobin ≥ 8.0 g/dL (RBC transfusions allowed)
• Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min OR creatinine based on age as follows:
• * No greater than 0.8 mg/dL (≤ 5 years of age)
• * No greater than 1.0 mg/dL (6 to 10 years of age)
• * No greater than 1.2 mg/dL (11 to 15 years of age)
• * No greater than 1.5 mg/dL (\> 15 years of age)
• Bilirubin ≤ 1.5 times upper limit of normal
• ALT ≤ 45 U/L
• Albumin ≥ 2 g/dL
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No evidence of active graft-vs-host disease
• No uncontrolled infection
• Recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy
• More than 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas)
• More than 1 week since prior growth factors, including those that support platelet or WBC number or function
• At least 1 week since prior biologic agents
• At least 2 weeks since prior local, palliative, small-port external-beam radiotherapy
• At least 6 months since prior total body irradiation (TBI), craniospinal radiotherapy, or radiotherapy to ≥ 50%of the pelvis
• At least 6 weeks since other prior substantial bone marrow radiotherapy (i.e., skull, spine, pelvis, or ribs)
• At least 3 months since prior stem cell transplantation or rescue without TBI
• No other concurrent investigational drugs
• No other concurrent anticancer agents, including chemotherapy, radiotherapy, immunotherapy, or biologic therapy
• No concurrent enzyme-inducing anticonvulsants, including any of the following:
• * Phenytoin
• * Phenobarbital
• * Felbamate
• * Primdone
• * Oxcarbazepine
• * Carbamazepine
• No concurrent agents that inhibit CYP3A4, including any of the following:
• * Itraconazole
• * Ketoconazole
• * Voriconazole